Evaluating Vancouver's supervised injection facility: Data and dollars, symbols and ethics

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 11, 2008, Pages 1105-1106

  Des Jarlais, Don C ^a   Arasteh, Kamyar ^a   Hagan, Holly ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; COST EFFECTIVENESS ANALYSIS; DRUG LEGISLATION; ETHICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INJECTION; INTRAVENOUS DRUG ABUSE; NOTE; PREVENTIVE HEALTH SERVICE; SOCIAL CONTROL;

EID: 56649094410     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.081678     Document Type: Note

References (10)

1. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ 2008;179:1143-51.
2. Committee on the Prevention of HIV Infection among Injecting Drug Users in High Risk Countries. Preventing HIV infection among injecting drug users in high risk countries: an assessment of the evidence. Washington (DC): Institute of Medicine; 2006.
3. Des Jarlais DC, Hagan H, Friedman S, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995;274:1226-31.
4. Stimson GV. AIDS and injecting drug use in the United Kingdom, 1987-1993: the policy response and the prevention of the epidemic. Soc Sci Med 1995;41:699-716.
5. Surveillance and Risk Assessment Division. Inventory of HIV incidence and prevalence studies in Canada. Ottawa (ON): Centre for Infectious Disease Prevention and Control, Infectious Diseases and Emergency Preparedness Branch, Public Health Agency of Canada; 2006.
6. Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health 2005;95:1439-44.
7. Des Jarlais DC, Perlis T, Arasteh K, et al. "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr 2004;35:158-66.
8. Kuyper LM, Hogg R, Montaner J, et al. The cost of inaction on HIV transmission among injection drug users and the potential for effective interventions. J Urban Health 2004;81:655-60.
9. Harris LT, Fiske S. Dehumanizing the lowest of the low. Psychol Sci 2006;17:847-53.
10. Des Jarlais DC. Harm reduction - a framework for incorporating science into drug policy [editorial]. Am J Public Health 1995;85:10-2.